Literature DB >> 3315978

Roles of IL-2 and antigen in the later stages of the primary antibody response.

J Sawada1, T Terao, M A Leon.   

Abstract

Spleen cells, obtained 2-5 days after in vivo priming with sheep erythrocytes (SRBC), were cultured to determine the presence of plaque-forming cell (PFC) precursors capable of developing into mature PFC under the influence of various stimulants. Lipopolysaccharide (LPS), added together with SRBC at the initiation of a 48-hr in vitro culture, enhanced the PFC response of primed spleen cells. In vivo priming for a minimum of 3 days was required, and maximal numbers of PFC were obtained from spleen cells primed for 4 days. Depletion of T lymphocytes from Day 3-primed spleen cells abrogated LPS-mediated enhancement, and addition of concanavalin A supernatants to the T-cell depleted system restored the enhancement, suggesting that LPS action required co-operation with a product(s) of activated T cells. Addition of various interleukin-2 preparations including recombinant human IL-2 to the system restored the LPS-mediated enhancement. The response of Day 3 cells from which T cells were eliminated as vigorously as possible was similarly restored by the addition of IL-2, LPS and antigen, suggesting that IL-2 reacts directly with PFC precursors that have developed IL-2 receptors. LPS-mediated enhancement, in the presence or absence of T cells, was also markedly dependent on the presence of SRBC during in vitro culture. These data suggest that, in co-operation with IL-2 and other co-factors, antigen plays a significant role in driving the later stages of differentiation and/or division of PFC precursors to mature PFC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315978      PMCID: PMC1453977     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

1.  Characterization of lymphocyte-activating factor (LAF) produced by the macrophage cell line, P388D1. I. Enhancement of LAF production by activated T lymphocytes.

Authors:  S B Mizel; J J Oppenheim; D L Rosenstreich
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

2.  A THREE-CELL INTERACTION REQUIRED FOR THE INDUCTION OF THE PRIMARY IMMUNE RESPONSE in vitro.

Authors:  D E Mosier; L W Coppleson
Journal:  Proc Natl Acad Sci U S A       Date:  1968-10       Impact factor: 11.205

3.  Stimulated rat T cell-derived inhibitory factor for cellular DNA synthesis (STIF). I. Isolation and characterization.

Authors:  K Chiba; T Nishimura; Y Hashimoto
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Comparison of methods for freezing interleukin-dependent murine cell lines.

Authors:  J Sawada; T Terao
Journal:  J Immunol Methods       Date:  1986-12-24       Impact factor: 2.303

6.  Interleukin 2-dependent T cell line acquires responsiveness to phorbol myristate acetate and lipopolysaccharide in the course of long-term culture.

Authors:  N Mukaida; T Kasahara; K Shioiri-Nakano; T Kawai
Journal:  Immunol Commun       Date:  1984

7.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

8.  Obligatory role of gamma interferon in T cell-replacing factor-dependent, antigen-specific murine B cell responses.

Authors:  M Brunswick; P Lake
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

9.  Monoclonal cytolytic T-cell lines.

Authors:  P E Baker; S Gillis; K A Smith
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

10.  Expression of Tac antigen on activated normal human B cells.

Authors:  M Tsudo; T Uchiyama; H Uchino
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.